Rajaraman Swaminathan, Ranganathan Rama, Viswanathan Shanta

Table 2. Incident cancer cases included in the survival analysis, among those registered in 1990–1999 and followed through 2001, PBCR, Chennai, India

Tumoursite/type

Number of cases included in survival analysis

Total

Passive follow-up only

Passive and active follow-up

Case 1a

Case 2b

Case 3c

Case 4d

Dead

Presumedalive atclosing date

Dead

Presumedalive atclosing date

Dead

Alive

Lost to follow-up

Dead

Alive

Lip

86

17

69

46

40

46

10

30

46

10

Tongue

988

371

617

693

295

693

54

241

693

54

Oral cavity

1662

528

1134

1052

610

1052

169

441

1052

169

Tonsil

250

107

143

214

36

214

16

20

214

16

Hypopharynx

1017

421

596

833

184

833

59

125

833

59

Oesophagus

2016

1028

988

1759

257

1759

59

198

1759

59

Stomach

2681

1392

1289

2277

404

2277

120

284

2277

120

Pancreas

328

190

138

291

37

291

23

14

291

23

Larynx

722

290

432

456

266

456

142

124

456

142

Lung

1806

1069

737

1574

232

1574

45

187

1574

45

Breast

3067

875

2192

1489

1578

1489

862

716

1489

862

Cervix

4438

1131

3307

1874

2564

1874

878

1686

1874

878

Ovary

808

321

487

487

321

487

138

183

487

138

Urinary bladder

442

172

270

305

137

305

62

75

305

62

Hodgkin lymphoma

298

92

206

171

127

171

74

53

171

74

Non-Hodgkin lymphoma

868

383

485

602

266

602

130

136

602

130

Lymphoid leukaemia

433

197

236

323

110

323

49

61

323

49

Myeloid leukaemia

465

277

188

365

100

365

35

65

365

35

Leukaemia, type unspecified

85

56

29

69

16

69

5

11

69

5

PBCR, population-based cancer registry.a Case 1: Passive follow-up only, with cancer cases not matched with those in the official mortality database presumed to be alive on the closing date.b Case 2: Passive and active follow-up, with cases lost to follow-up presumed to be alive on the closing date.c Case 3: Passive and active follow-up, with cases lost to follow-up censored on the last date their survival status was known.d Case 4: Passive and active follow-up, with cases lost to follow-up excluded from survival analysis.